SCHEMBL245102

SCHEMBL245102

COC(=O)c1cc(Cl)cc(Cl)n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 3/20 0.45
NQO2 P16083 5/20 0.44
ALDH1A1 P00352 6/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 3/20 0.41
NPSR1 Q6W5P4 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
NOTUM Q6P988 1/20 0.40
ABL1 P00519 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29411203 1.00 MAPK1 (0.46) MAPK1KDM4ENQO2ALDH1A1L3MBTL1
SCHEMBL1137177 0.90 NQO2 (0.47) MAPK1KDM4ENQO2ALDH1A1L3MBTL1
SCHEMBL7078655 0.83 ALOX15 (0.45) MAPK1KDM4ENQO2ALDH1A1L3MBTL1
SCHEMBL3403855 0.83 NQO2 (0.47) MAPK1KDM4ENQO2ALDH1A1MAPT
SCHEMBL29867038 0.83 KDM4E (0.52) MAPK1KDM4ENQO2ALDH1A1L3MBTL1
SCHEMBL9297992 0.83 NQO2 (0.43) MAPK1KDM4ENQO2ALDH1A1L3MBTL1
SCHEMBL29427729 0.83 NQO2 (0.47) MAPK1KDM4ENQO2ALDH1A1MAPT
SCHEMBL16232808 0.83 KMT2A (0.46) MAPK1KDM4ENQO2ALDH1A1L3MBTL1
SCHEMBL21200349 0.83 KDM4E (0.52) MAPK1KDM4ENQO2ALDH1A1L3MBTL1
SCHEMBL30305401 0.83 ALOX15 (0.45) MAPK1KDM4ENQO2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382290-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-12-18 US disclosed
WO-2025215110-A1 NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS LES LABORATOIRES SERVIER (FR) 2025-10-16 WO disclosed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2025-07-24 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
EP-4522608-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2025-03-19 EP disclosed
US-20250059182-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS, INC 2025-02-20 US disclosed
US-12195449-B2 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof BEIGENE, LTD. (KY) 2025-01-14 US disclosed
US-20240317714-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2024-09-26 US disclosed
US-5972975-A Substituted 2-aminopyridines as inhibitors of nitric oxide synthase MERCK & CO., INC. (US) 1999-10-26 US disclosed
EP-0949248-A1 6-(NONSUBSTITUTED OR SUBSTITUTED) PHENOXYPICOLINIC ACIDS, PROCESS OF PREPARING THE SAME, AND AGRICULTURAL/HORTICULTURAL GERMICIDES CONTAINING THE SAME KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1999-10-13 EP disclosed
EP-0858444-A1 CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-08-19 EP disclosed
US-5750549-A ANTIINFLAMMATORY AGENTS OR ANALGESICS MERCK & CO., INC. (US) 1998-05-12 US disclosed
WO-1997014671-A1 CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-04-24 WO disclosed
WO-1996018616-A1 SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-06-20 WO disclosed
US-4786317-A 4-phenoxy-pyridines having herbicidal activity CELAMERCK GMBH & CO. KG (DE) 1988-11-22 US disclosed
US-4655824-A Certain trifluoromethoxy-phenoxy-pyridines having herbicidal activity CELAMERCK GMBH & CO. KG (DE) 1987-04-07 US disclosed
EP-0086375-B1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE CELAMERCK GmbH & Co. KG (DE) 1986-04-09 EP disclosed
EP-0086375-A2 Pyridine derivatives, their preparation and use CELAMERCK GmbH & Co. KG (DE) 1983-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317714-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 MAPK1 378/4885KDM4E 1979/4885NQO2 2812/4885
US-20250382290-A1 SALTS OF SOS1 INHIBITORS SOS1, SOS2, SOST MAPK1 486/4885KDM4E 3149/4885NQO2 2986/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 MAPK1 576/4885KDM4E 3245/4885NQO2 3144/4885
US-20250059182-A1 SOS1 INHIBITORS SOS1, SOS2, SOST MAPK1 608/4885KDM4E 2892/4885NQO2 3045/4885
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB MAPK1 280/4885KDM4E 1355/4885NQO2 928/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 MAPK1 576/4885KDM4E 3245/4885NQO2 3144/4885
US-12195449-B2 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof HIPK1, HIPK3, HIPK2 MAPK1 378/4885KDM4E 1979/4885NQO2 2812/4885
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 MAPK1 366/4885KDM4E 1865/4885NQO2 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.